Myriad Genetics (MYGN) reported Q3 EPS of ($0.19), $0.13 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $156.4 million versus the consensus estimate of $170.58 million.
GUIDANCE:
Myriad Genetics sees FY2022 EPS of ($0.35)-($0.30), versus the consensus of ($0.06). Myriad Genetics sees FY2022 revenue of $668-672 million, versus the consensus of $692.2 million.